Furazolidone (Furoxone) was found to be a potent inhibitor of monoamine oxidase (MAO) in man. It produced marked supersensitivity to tyramine and amphetamine, inhibition of intestinal MAO and increased urinary excretion of tryptamine. Continued administration of furazolidone produced a cumulative inhibition of MAO to the extent that chronic therapy would be expected to carry a significant risk of hypertensive crisis. However, a brief period of furazolidone administration should be free from this hazard. A safe method of quantifying changes in pressor sensitivity to tyramine is described. There is a semilogarithmic correlation between changes in response to tyramine and monoamine oxidase activity measured biochemically.
No takes yet. Share an insight, caveat, or question.
Pettinger et al. (1968) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: